ArticleOphthalmology science

Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice.

Robyn Guymer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.